Printed from the IBC Life Sciences Web site on May 4, 2016 2:08 AM ET.
Page location: http://www.ibclifesciences.com/20324.xml
March 3-5, 2010 in Carlsbad, California
WESTBOROUGH, MASS. -- January 12, 2009 -- This year's Antibody Development & Production conference, presented by IBC Life Sciences, brings together experts from upstream and downstream processing to address how technical, scientific and regulatory changes in the industry are impacting companies of all sizes.
Keynote speaker, G. Steven Burrill, will present "Life Sciences Navigating the Sea Change" to tackle major issues facing the life sciences industry as well as solutions for prospering despite these challenges.
Additional keynote speaker, Dana Anderson, Ph.D., will discuss the impact and dramatic growth in the use of therapeutic monoclonal antibodies during "Industrialization of mAb Production: Implications Challenges and Opportunities".
Thomas Ryll, a recently added keynote, will summarize development work conducted at Biogen Idec beyond the sole focus on improvements in tier during his presentation, "Are there Drivers Left for Further Cell Culture Optimization?"
"With so much change in the industry, I'm excited to include presentations that will energize, encourage, and enable attendees to flourish," says Conference Producer Barry Walsh. "I think people are realizing that there is no replacement for meeting face-to-face and hearing directly from key players in the industry."
Featured talks include "Battling the Biological and Biochemical Challenges to Efficient Upstream/Downstream Process Integration" and "Improving Bulk Process Transfer at Centocor: The 'Process-Fit-To-Plant'Program" by Dr. Robert Kiss and Dr. Charles Goochee respectively.
Additional content includes five strategic discussion forums, extensive case studies, such as "Results from the CMC Biotech Working Group QbD Case Study" co-presented by Eli Lilly and Company and Pfizer Inc. as well as an exhibit hall on March 3-4. The exhibit hall will showcase more than 65 supplier companies, many of which are planning to launch new products at Antibody Development & Production.
This event is part of Biopharmaceutical Development & Production Week, March 1-5, which includes concurrent event Recombinant Protein & Complex Biologic Development & Production and co-located conferences Process & Product Validation, Technology Transfer, and Outsourcing. Attendees may choose to attend one conference or the full week with an all access pass.
Complete details can be found at www.ibclifesciences.com/BDPWeek.
For a press pass please contact email@example.com.
IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. For more information, visit www.IBCLifeSciences.com.